已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Real‐world experience with Curcumin–QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study

医学 内科学 溃疡性结肠炎 胃肠病学 回顾性队列研究 队列 皮质类固醇 疾病
作者
Henit Yanai,Nir Salomon,Adi Lahat,Bella Ungar,Rami Eliakim,O Kriger-Sharabi,Hilla Reiss‐Mintz,Benjamin Koslowsky,Ariella Bar‐Gil Shitrit,Natalie Tamir‐Degabli,Iris Dotan,Eran Zittan,Nitsan Maharshak,Ayal Hirsch,Shomron Ben‐Horin,Uri Kopylov
出处
期刊:Alimentary Pharmacology & Therapeutics [Wiley]
卷期号:58 (2): 175-181 被引量:19
标识
DOI:10.1111/apt.17538
摘要

Summary Background Curcumin and QingDai (QD, Indigo) have been shown to be effective for treating active ulcerative colitis (UC). Aim To evaluate the real‐world experience with the Curcumin–QingDai (CurQD) herbal combination to induce remission in active UC. Methods A retrospec‑tive multicentre adult cohort study from five tertiary academic centres (2018–2022). Active UC was defined as a Simple Clinical Colitis Activity Index (SCCAI) ≥ 3. Patients were induced by CurQD. The primary outcome was clinical remission at weeks 8–12, defined as SCCAI ≤2 and a decrease ≥3 points from baseline. Secondary outcomes were clinical response (SCCAI decrease ≥3 points), corticosteroid‐free remission, faecal calprotectin (FC) response (reduction ≥50%), FC normalisation (FC ≤100 μg/g for patients with FC ≥300 μg/g at baseline), and safety. All outcomes were analysed for patients who were maintaining stable treatment. Results Eighty‐eight patients were included; 50% were biologics/small molecules experienced, and 36.5% received ≥2 biologics/small molecules. Clinical remission was achieved in 41 (46.5%), and clinical response in 53 (60.2%). Median SCCAI decreased from 7 (IQR:5–9) to 2 (IQR:1–3); p < 0.0001. Of the 26 patients on corticosteroids at baseline, seven achieved corticosteroid‐free remission. Among 43 biologics/small molecules experienced patients, clinical remission was achieved in 39.5% and clinical response in 58.1%. FC normalisation and response were achieved in 17/29 and 27/33, respectively. Median FC decreased from 1000 μg/g (IQR:392–2772) at baseline to 75 μg/g (IQR:12–136) at the end of inductions ( n = 30 patients with paired samples); p < 0.0001. No overt safety signals emerged. Conclusion In this real‐world cohort, CurQD effectively induced clinical and biomarker remission in patients with active UC, including patients who were biologics/small molecules experienced.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
2秒前
2秒前
Spike完成签到,获得积分10
4秒前
5秒前
向日葵完成签到,获得积分10
5秒前
6秒前
超级无敌好吃完成签到,获得积分10
6秒前
7秒前
Zen完成签到 ,获得积分10
8秒前
爱如少年发布了新的文献求助10
8秒前
Haisilas完成签到 ,获得积分10
9秒前
9秒前
专一的白发布了新的文献求助10
10秒前
11秒前
铭铭完成签到 ,获得积分10
12秒前
彭于晏的应助被00hello00采纳,获得10
13秒前
自私的猫完成签到,获得积分10
15秒前
晚风完成签到 ,获得积分10
16秒前
16秒前
17秒前
qingshenggao完成签到,获得积分10
17秒前
企鹅完成签到 ,获得积分10
18秒前
科研通AI6.4的应助被wentian采纳,获得10
20秒前
21秒前
科研通AI6.2的应助被俏皮以旋采纳,获得10
21秒前
十一一完成签到 ,获得积分10
22秒前
共享精神的应助被俭朴灵竹采纳,获得10
25秒前
倾解完成签到,获得积分10
25秒前
星星完成签到 ,获得积分10
29秒前
30秒前
寒冷水香完成签到,获得积分10
30秒前
32秒前
33秒前
34秒前
斯文败类的应助被zxinran0408采纳,获得10
36秒前
大模型的应助被Okpooko采纳,获得10
36秒前
专一的白发布了新的文献求助10
36秒前
Tenax完成签到,获得积分10
37秒前
强健的秋发布了新的文献求助10
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184646
求助须知:如何正确求助?哪些是违规求助? 9573637
关于积分的说明 21832477
捐赠科研通 7781914
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558498
邀请新用户注册赠送积分活动 2481003